The International Vaccine Institute (IVI) and the Technical University of Denmark's (DTU) National Food Institute announced today a joint effort to strengthen external quality assurance programs for diagnostic laboratories in Asia to confront the challenges of rising antimicrobial resistance (AMR) in the region.
The partnership was established following the award of a Fleming Fund Regional Grant with DTU as the lead grantee and will carry out the project under the name EQASIA (Strengthening External Quality Assurance for AMR in Asia).
It is crucial to address the quality of bacteriology diagnostics at the regional level to ensure generated lab data is accurate and comparable according to international standards.
Although laboratories in the Asian region have made advances locally, the range of differing capacities and limited efforts at regional coordination signal the need for standardized regional external quality assurance (EQA). Confronting AMR requires high-quality data and regional coordination .
Through EQASIA, the two institutes will map the coverage, availability and uptake of external quality assurance programs across reference laboratories with the overall aim of improving the quality of AMR surveillance data.
Quality-assured data is essential for developing nuanced treatment guidelines and tailored strategies to prevent the emergence and spread of drug-resistant infections.
Taking part in EQASIA is an ideal opportunity for us to ensure synergy with, and add impact to, our previous efforts to support AMR surveillance in the Asian region. Assessing the full impact of AMR will require a harmonized effort between data collection and sharing, and regional and global policy-making." Dr Marianne Holm, Epidemiology & Public Health Research Lead, IVI Data collection and informed policy-making go hand in hand . Related Stories
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology